Literature DB >> 30267014

State-dependent effects of the D2 partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia.

Susan F Sonnenschein1, Kathryn M Gill2, Anthony A Grace2.   

Abstract

Aripiprazole is an antipsychotic drug characterized by partial agonist activity at D2 receptors to normalize both hyperdopaminergic and hypodopaminergic states. Traditional D2 antagonist antipsychotic drugs have been shown previously to reduce dopamine neuron activity through action on D2 autoreceptors to produce an overexcitation-induced cessation of cell firing, referred to as depolarization block. It is unclear whether aripiprazole reduces dopamine neuron activity via inhibition or, as seen following D2 antagonist administration, depolarization block. The impact of acute and repeated aripiprazole treatment was examined in the methylazoxymethanol acetate (MAM) rodent model to observe its effects on a hyperdopaminergic system, compared to normal rats. We found that administration of aripiprazole acutely or after 1 or 7 days of withdrawal from 21-day repeated treatment led to a decrease in the number of spontaneously active dopamine neurons in MAM rats but not in controls. This reduction was not reversed by apomorphine (100-200 µg/kg i.p. or 20 µg/kg i.v.) administration, suggesting that it was not due to depolarization block. In contrast, 1 h after induction of depolarization block of dopamine neurons by acute haloperidol treatment (0.6 mg/kg i.p.), aripiprazole (1 mg/kg, i.p.) reversed the depolarization block state. Therefore, aripiprazole rapidly reduced the hyperdopaminergic activity selectively in MAM rats. The reduction is unlikely due to depolarization block and persists following 7-day withdrawal from repeated treatment. Aripiprazole also removes haloperidol-induced depolarization block in MAM rats, which may underlie the acute psychotic state often observed with switching to this treatment.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30267014      PMCID: PMC6333840          DOI: 10.1038/s41386-018-0219-1

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  62 in total

1.  Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery.

Authors:  Anne-Noël Samaha; Greg E Reckless; Philip Seeman; Mustansir Diwan; José N Nobrega; Shitij Kapur
Journal:  Biol Psychiatry       Date:  2008-03-04       Impact factor: 13.382

2.  Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes.

Authors:  Guy Chouinard; Virginie-Anne Chouinard
Journal:  Psychother Psychosom       Date:  2008-01-25       Impact factor: 17.659

3.  Intrastriatal kainic acid: acute effects on electrophysiological and biochemical measures of nigrostriatal dopaminergic activity.

Authors:  J J Braszko; M J Bannon; B S Bunney; R H Roth
Journal:  J Pharmacol Exp Ther       Date:  1981-02       Impact factor: 4.030

4.  Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study.

Authors:  S Silvestri; M V Seeman; J C Negrete; S Houle; C M Shammi; G J Remington; S Kapur; R B Zipursky; A A Wilson; B K Christensen; P Seeman
Journal:  Psychopharmacology (Berl)       Date:  2000-10       Impact factor: 4.530

5.  Differential enhancement of behavioral sensitivity to apomorphine following chronic treatment of rats with (-)-sulpiride and haloperidol.

Authors:  N Montanaro; R Dall'Olio; O Gandolfi; A Vaccheri
Journal:  Eur J Pharmacol       Date:  1982-06-16       Impact factor: 4.432

6.  7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.

Authors:  T Kikuchi; K Tottori; Y Uwahodo; T Hirose; T Miwa; Y Oshiro; S Morita
Journal:  J Pharmacol Exp Ther       Date:  1995-07       Impact factor: 4.030

7.  The control of firing pattern in nigral dopamine neurons: burst firing.

Authors:  A A Grace; B S Bunney
Journal:  J Neurosci       Date:  1984-11       Impact factor: 6.167

8.  Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders.

Authors:  Scott A Schobel; Nicole M Lewandowski; Cheryl M Corcoran; Holly Moore; Truman Brown; Dolores Malaspina; Scott A Small
Journal:  Arch Gen Psychiatry       Date:  2009-09

9.  Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain.

Authors:  J Semba; A Watanabe; S Kito; M Toru
Journal:  Neuropharmacology       Date:  1995-07       Impact factor: 5.250

10.  A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia.

Authors:  Daniel J Lodge; Margarita M Behrens; Anthony A Grace
Journal:  J Neurosci       Date:  2009-02-25       Impact factor: 6.167

View more
  8 in total

1.  The mGluR2/3 agonist pomaglumetad methionil normalizes aberrant dopamine neuron activity via action in the ventral hippocampus.

Authors:  Susan F Sonnenschein; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2020-07-14       Impact factor: 7.853

Review 2.  Insights on current and novel antipsychotic mechanisms from the MAM model of schizophrenia.

Authors:  Susan F Sonnenschein; Anthony A Grace
Journal:  Neuropharmacology       Date:  2019-05-08       Impact factor: 5.250

Review 3.  Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention.

Authors:  Felipe V Gomes; Anthony A Grace
Journal:  Int J Mol Sci       Date:  2021-04-25       Impact factor: 5.923

Review 4.  Dysregulation of Midbrain Dopamine System and the Pathophysiology of Schizophrenia.

Authors:  Susan F Sonnenschein; Felipe V Gomes; Anthony A Grace
Journal:  Front Psychiatry       Date:  2020-06-30       Impact factor: 4.157

Review 5.  Recent Discussions on Dopamine Supersensitivity Psychosis: Eight Points to Consider When Diagnosing Treatment-Resistant Schizophrenia.

Authors:  Nobuhisa Kanahara; Hiroshi Kimura; Yasunori Oda; Fumiaki Ito; Masaomi Iyo
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708

Review 6.  Insights into the Promising Prospect of G Protein and GPCR-Mediated Signaling in Neuropathophysiology and Its Therapeutic Regulation.

Authors:  Md Mominur Rahman; Md Rezaul Islam; Sadia Afsana Mim; Nasrin Sultana; Dinesh Kumar Chellappan; Kamal Dua; Mohammad Amjad Kamal; Rohit Sharma; Talha Bin Emran
Journal:  Oxid Med Cell Longev       Date:  2022-09-21       Impact factor: 7.310

Review 7.  Emerging therapeutic targets for schizophrenia: a framework for novel treatment strategies for psychosis.

Authors:  Susan F Sonnenschein; A Grace
Journal:  Expert Opin Ther Targets       Date:  2020-11-26       Impact factor: 6.902

8.  Adult stress exposure blunts dopamine system hyperresponsivity in a neurodevelopmental rodent model of schizophrenia.

Authors:  Millie Rincón-Cortés; Anthony A Grace
Journal:  Schizophrenia (Heidelb)       Date:  2022-03-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.